We also investigate the maximum vital goals in prostate cancer therapy such as AR, prostate specific antigen (PSA), AKT, cyclin B1, cyclin dependent kinase (CDK1), phospho‐androgen receptor (p‐AR), and phospho‐CDK1 (p‐CDK1: T161) expression. Here, KLK3 is linked to prostate carcinoma.